TRIM52

Summary

TRIM52 (tripartite motif containing 52, HGNC:19024) is a protein-coding gene on chromosome 5q35.3, encoding E3 ubiquitin-protein ligase TRIM52 (Q96A61). E3 ubiquitin-protein ligase.

Enables transcription coactivator activity and ubiquitin protein ligase activity. Involved in several processes, including positive regulation of NF-kappaB transcription factor activity; positive regulation of canonical NF-kappaB signal transduction; and protein autoubiquitination. Located in cytosol and nucleus.

Source: NCBI Gene 84851 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 44 total
• MANE Select transcript: NM_001346048

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19024
Approved symbol	TRIM52
Name	tripartite motif containing 52
Location	5q35.3
Locus type	gene with protein product
Status	Approved
Aliases	RNF102
Ensembl gene	ENSG00000183718
Ensembl biotype	protein_coding
OMIM	619265
Entrez	84851

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000503005, ENST00000510796, ENST00000513146, ENST00000514805, ENST00000611618, ENST00000612671, ENST00000685507, ENST00000686030, ENST00000688015, ENST00000691252, ENST00000880616

RefSeq mRNA: 5 — MANE Select: NM_001346048 NM_001346048, NM_001346049, NM_001346050, NM_001346051, NM_032765

CCDS: CCDS4467, CCDS93843, CCDS93844, CCDS93845, CCDS93846

Canonical transcript exons

ENST00000688015 — 2 exons

Exon	Start	End
ENSE00003933195	181255147	181256859
ENSE00003934803	181260001	181261143

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 91.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.5291 / max 186.5970, expressed in 1702 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
65377	5.2880	1520
65376	4.2412	1262

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	91.85	gold quality
cerebellar hemisphere	UBERON:0002245	90.33	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.25	gold quality
cerebellar cortex	UBERON:0002129	90.12	gold quality
cerebellum	UBERON:0002037	88.71	gold quality
right uterine tube	UBERON:0001302	88.54	gold quality
left lobe of thyroid gland	UBERON:0001120	88.44	gold quality
right lobe of thyroid gland	UBERON:0001119	88.35	gold quality
granulocyte	CL:0000094	88.28	gold quality
pituitary gland	UBERON:0000007	88.12	gold quality
adenohypophysis	UBERON:0002196	87.98	gold quality
left ovary	UBERON:0002119	87.85	gold quality
thyroid gland	UBERON:0002046	87.77	gold quality
body of pancreas	UBERON:0001150	87.56	gold quality
monocyte	CL:0000576	87.08	gold quality
right ovary	UBERON:0002118	87.07	gold quality
mononuclear cell	CL:0000842	87.04	gold quality
leukocyte	CL:0000738	87.02	gold quality
endocervix	UBERON:0000458	86.86	gold quality
right coronary artery	UBERON:0001625	86.77	gold quality
metanephros cortex	UBERON:0010533	86.74	gold quality
popliteal artery	UBERON:0002250	86.63	gold quality
tibial artery	UBERON:0007610	86.62	gold quality
apex of heart	UBERON:0002098	86.58	gold quality
body of uterus	UBERON:0009853	86.56	gold quality
tibial nerve	UBERON:0001323	86.49	gold quality
lymph node	UBERON:0000029	86.14	gold quality
spleen	UBERON:0002106	86.11	gold quality
lower esophagus muscularis layer	UBERON:0035833	85.99	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.98	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-6379	no	217.79
E-ANND-3	no	4.59

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting TRIM52, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-4762-5P	99.57	68.54	1424
HSA-MIR-136-5P	99.50	67.26	1153
HSA-MIR-516A-3P	99.46	67.96	1378
HSA-MIR-516B-3P	99.46	67.96	1378
HSA-MIR-7162-5P	99.46	68.08	1368
HSA-MIR-6853-3P	99.36	70.79	1558
HSA-MIR-3678-3P	99.31	67.10	1432
HSA-MIR-6828-5P	99.31	69.21	1433
HSA-MIR-1273H-3P	99.29	67.55	980
HSA-MIR-491-3P	98.88	68.86	1224
HSA-MIR-2467-3P	98.65	67.18	1969
HSA-MIR-4726-3P	98.49	63.89	1385
HSA-MIR-4446-3P	97.91	64.29	991
HSA-MIR-647	97.73	67.79	927
HSA-MIR-6781-3P	97.44	66.85	970

Literature-anchored findings (GeneRIF, showing 9)

• these data suggested that TRIM52 was a positive regulator of the NF-kappaB pathway. (PMID:28073078)
• TRIM52 can promote cell proliferation and HBx may regulate TRIM52 expression via the NF-kappaB signaling pathway in Hepatitis B Virus-Associated Hepatocellular Carcinoma. (PMID:29089476)
• Our findings suggest that TRIM52 up-regulation promotes proliferation, migration and invasion of HCC cells through the ubiquitination of PPM1A. (PMID:29898761)
• TRIM52 plays an oncogenic role in ovarian cancer development. (PMID:30185771)
• Based on these data, it was speculated that TRIM52 is critical for lung cancer progression and that downregulation of TRIM52 could inhibit cell proliferation by blocking cell cycle progression. (PMID:31002351)
• A repetitive acidic region contributes to the extremely rapid degradation of the cell-context essential protein TRIM52. (PMID:31133683)
• TRIM52 positively mediates NF-kappaB to promote the growth of human benign prostatic hyperplasia cells through affecting TRAF2 ubiquitination. (PMID:32898524)
• Long non-coding RNA TRIM52-AS1 sponges microRNA-577 to facilitate diffuse large B cell lymphoma progression via increasing TRIM52 expression. (PMID:35676608)
• TRIM52 knockdown inhibits proliferation, inflammatory responses and oxidative stress in IL-1beta-induced synovial fibroblasts to alleviate temporomandibular joint osteoarthritis. (PMID:38520211)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:dkey-29p10.4	ENSDARG00000017173
mus_musculus	Trim52	ENSMUSG00000022113
rattus_norvegicus	Trim52	ENSRNOG00000024509

Paralogs (80): MID2 (ENSG00000080561), TRIM9 (ENSG00000100505), MID1 (ENSG00000101871), MEFV (ENSG00000103313), TRIM35 (ENSG00000104228), TRIM14 (ENSG00000106785), TRIM37 (ENSG00000108395), TRIM2 (ENSG00000109654), TRIM3 (ENSG00000110171), TRIM38 (ENSG00000112343), TRIM62 (ENSG00000116525), TRIM67 (ENSG00000119283), TRIM32 (ENSG00000119401), BSPRY (ENSG00000119411), TRIM25 (ENSG00000121060), TRIM6 (ENSG00000121236), TRIM24 (ENSG00000122779), TRIM51 (ENSG00000124900), TRIM28 (ENSG00000130726), TRIM21 (ENSG00000132109), TRIM5 (ENSG00000132256), TRIM22 (ENSG00000132274), TRIM47 (ENSG00000132481), TRIM45 (ENSG00000134253), TRIM29 (ENSG00000137699), TRIM54 (ENSG00000138100), PML (ENSG00000140464), TRIM65 (ENSG00000141569), TRIM43B (ENSG00000144010), TRIM43 (ENSG00000144015), TRIM7 (ENSG00000146054), TRIM41 (ENSG00000146063), TRIM50 (ENSG00000146755), TRIM4 (ENSG00000146833), TRIM55 (ENSG00000147573), TRIM48 (ENSG00000150244), TRIM36 (ENSG00000152503), TRIM11 (ENSG00000154370), TRIM74 (ENSG00000155428), TRIM42 (ENSG00000155890)

Protein

Protein identifiers

E3 ubiquitin-protein ligase TRIM52 — Q96A61 (reviewed: Q96A61)

Alternative names: RING finger protein 102, Tripartite motif-containing protein 52

All UniProt accessions (7): A0A8I5KQM7, A0A8I5KRY2, A0A8I5KW90, A0A8I5KXP2, A0A8I5KXQ2, A0A8I5KYD8, Q96A61

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin-protein ligase. Positively regulates the NF-kappa-B signaling pathway. (Microbial infection) Exhibits antiviral activity against Japanese encephalitis virus (JEV). Ubiquitinates the viral non-structural protein 2 (NS2A) and targets it for proteasome-mediated degradation.

Subunit / interactions. (Microbial infection) Interacts with Japanese encephalitis virus non-structural protein 2 (NS2A); mediates the ubiquitination of NS2A, targeting it for proteasome-mediated degradation.

Subcellular location. Cytoplasm. Cytosol. Nucleus.

Post-translational modifications. Autoubiquitinated. Polyubiquitinated. Undergoes extremely rapid proteolytic degradation by the proteasome.

Domain organisation. The RING-type zinc finger domain is essential for its E3 ubiquitin-protein ligase activity, ability to positively regulate the NF-kappa-B signaling pathway and its antiviral activity.

Induction. Up-regulated by Golgi stress-inducing agents such nigericin, trichostatin, tetoposide, campothecin and brefeldin A. Up-regulated by IL1B/interleukin-1 beta and TNFA/TNF.

Pathway. Protein modification; protein ubiquitination.

Miscellaneous. Arose via a partial duplication of the TRIM41 gene, followed by independent loss or pseudogenization of TRIM52 in multiple mammalian and primate lineages.

Similarity. Belongs to the TRIM/RBCC family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96A61-1	1	yes
Q96A61-2	2

RefSeq proteins (5): NP_001332977, NP_001332978, NP_001332979, NP_001332980, NP_116154 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000315	Znf_B-box	Domain
IPR001841	Znf_RING	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR017907	Znf_RING_CS	Conserved_site
IPR050143	TRIM/RBCC	Family

Pfam: PF00643, PF15227

UniProt features (11 total): binding site 4, zinc finger region 2, splice variant 2, chain 1, sequence conflict 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96A61-F1	67.44	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 227; 230; 249; 255

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 90 (showing top): GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, BROWNE_HCMV_INFECTION_16HR_UP, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_PROTEIN_AUTOUBIQUITINATION, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_DEFENSE_RESPONSE_TO_VIRUS, BROWNE_HCMV_INFECTION_10HR_UP, GOBP_POSITIVE_REGULATION_OF_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_RESPONSE_TO_VIRUS, GOMF_ACYLTRANSFERASE_ACTIVITY, THUM_SYSTOLIC_HEART_FAILURE_DN, STEIN_ESRRA_TARGETS_UP, GOMF_AMINOACYLTRANSFERASE_ACTIVITY, GOMF_UBIQUITIN_LIKE_PROTEIN_LIGASE_ACTIVITY

GO Biological Process (7): protein ubiquitination (GO:0016567), positive regulation of canonical NF-kappaB signal transduction (GO:0043123), innate immune response (GO:0045087), defense response to virus (GO:0051607), protein autoubiquitination (GO:0051865), positive regulation of signal transduction (GO:0009967), positive regulation of DNA-templated transcription (GO:0045893)

GO Molecular Function (5): transcription coactivator activity (GO:0003713), zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
protein modification by small protein conjugation	1
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
positive regulation of intracellular signal transduction	1
immune response	1
defense response to symbiont	1
defense response	1
response to virus	1
protein ubiquitination	1
signal transduction	1
regulation of signal transduction	1
positive regulation of cell communication	1
positive regulation of signaling	1
positive regulation of response to stimulus	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
transcription coregulator activity	1
positive regulation of DNA-templated transcription	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
catalytic activity	1
cation binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

830 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRIM52	TRAT1	Q6PIZ9	598
TRIM52	TRIM14	Q14142	595
TRIM52	TRIM55	Q9BYV6	507
TRIM52	TRIM16	O95361	464
TRIM52	TRIM59	Q8IWR1	463
TRIM52	TRIM51	Q9BSJ1	459
TRIM52	TRIM23	P36406	457
TRIM52	TRIM74	Q86UV6	454
TRIM52	PRR7	Q8TB68	449
TRIM52	BBOX1	O75936	447
TRIM52	TRIM32	Q13049	446
TRIM52	TRIM54	Q9BYV2	438
TRIM52	TRIM73	Q86UV7	435
TRIM52	TRIM56	Q9BRZ2	433
TRIM52	TRIM77	I1YAP6	421

IntAct

9 interactions, top by confidence:

A	B	Type	Score
TRIM52	TRIM41	psi-mi:“MI:0915”(physical association)	0.550
RNF126	TRIM52	psi-mi:“MI:0915”(physical association)	0.370
TRIM52	RNF114	psi-mi:“MI:0915”(physical association)	0.370
TRIM52	MEIOC	psi-mi:“MI:0914”(association)	0.350
gcvPA	TRIM52	psi-mi:“MI:0915”(physical association)	0.000
TRIM52	tktA	psi-mi:“MI:0915”(physical association)	0.000
RSPH1	TRIM52	psi-mi:“MI:0915”(physical association)	0.000
TRIM52	UBA1	psi-mi:“MI:0220”(ubiquitination reaction)	0.000

BioGRID (138): PPM1A (Affinity Capture-Western), TRIM52 (Affinity Capture-Western), TRIM52 (Affinity Capture-MS), TRIM52 (Affinity Capture-Western), PPM1A (Affinity Capture-Western), TOP2A (Affinity Capture-MS), TOP2B (Affinity Capture-MS), OIP5 (Affinity Capture-MS), CCDC88A (Affinity Capture-MS), CEP350 (Affinity Capture-MS), ALMS1 (Affinity Capture-MS), MYO5C (Affinity Capture-MS), PLEKHA5 (Affinity Capture-MS), NCAPH2 (Affinity Capture-MS), MYO9A (Affinity Capture-MS)

ESM2 similar proteins: A0A1D5NS60, A0A3B3IT52, A5D7E9, A6NDR6, A6NMN3, A7MBB4, A8T6P4, M0R5D6, M3WHG5, O35668, O93567, O95125, P03127, P0C7M4, P0DPR2, P54256, P54257, P56163, P58283, P70278, Q08D68, Q1HKZ5, Q4V8F1, Q503Y8, Q5DTT4, Q5REX1, Q5XIX0, Q6INH1, Q6P0Q8, Q6ZMN7, Q76I76, Q76N89, Q7TSC3, Q7ZX20, Q811L6, Q86XG9, Q8CFH6, Q8IWB6, Q8K4P8, Q8NHV9

Diamond homologs: A0A3B3IT33, A6NCK2, A6NDI0, A6NGJ6, A6NI03, A6NLI5, B0BLU1, C9J1S8, I1YAP6, O00478, O00481, O15344, O75677, O75678, O75679, O76064, P0CI25, P0CI26, P18892, P19474, P62603, P86448, P86449, Q13410, Q2HJ46, Q3C1V9, Q3TL54, Q4KLN8, Q5EBN2, Q5PQN2, Q5R4I2, Q5R996, Q61510, Q62556, Q6INS5, Q6MFY8, Q6UX41, Q6UXE8, Q6ZWI9, Q7T308

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	TRIM52	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

244 predictions. Top by Δscore:

Variant	Effect	Δscore
5:181260020:T:TA	donor_gain	1.0000
5:181255938:A:C	acceptor_gain	0.9900
5:181257416:A:AC	donor_gain	0.9900
5:181257417:C:CC	donor_gain	0.9900
5:181259998:CAC:C	donor_loss	0.9900
5:181260015:C:CT	donor_gain	0.9900
5:181260016:C:CT	donor_gain	0.9900
5:181259999:A:AC	donor_gain	0.9800
5:181260000:C:CC	donor_gain	0.9800
5:181260008:TCCTG:T	donor_gain	0.9700
5:181260009:CCTGC:C	donor_gain	0.9700
5:181259705:ACGTC:A	donor_gain	0.9300
5:181259706:CGTCC:C	donor_gain	0.9300
5:181257412:T:TA	donor_gain	0.9200
5:181260014:A:AC	donor_gain	0.9200
5:181260000:CCTG:C	donor_gain	0.8900
5:181256130:CTT:C	acceptor_gain	0.8800
5:181256131:TTT:T	acceptor_gain	0.8800
5:181259709:C:A	donor_gain	0.8700
5:181259705:A:AC	donor_gain	0.8600
5:181259706:C:CC	donor_gain	0.8600
5:181259715:CA:C	donor_gain	0.8600
5:181260011:TGCAC:T	donor_gain	0.8500
5:181257418:T:C	donor_gain	0.8400
5:181255934:CAATA:C	acceptor_gain	0.8300
5:181259873:T:TG	acceptor_gain	0.8300
5:181259705:ACGT:A	donor_gain	0.8100
5:181259706:CGTC:C	donor_gain	0.8100
5:181256137:A:T	acceptor_gain	0.7400
5:181256650:CTT:C	acceptor_gain	0.7300

AlphaMissense

1923 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:181260697:G:C	F39L	0.999
5:181260697:G:T	F39L	0.999
5:181260699:A:G	F39L	0.999
5:181260698:A:G	F39S	0.997
5:181260267:A:G	C183R	0.996
5:181260698:A:C	F39C	0.996
5:181260756:A:G	C20R	0.996
5:181260244:A:C	F190L	0.995
5:181260244:A:T	F190L	0.995
5:181260246:A:G	F190L	0.995
5:181260703:G:C	H37Q	0.995
5:181260703:G:T	H37Q	0.995
5:181260747:A:G	C23R	0.995
5:181260103:G:C	F237L	0.994
5:181260103:G:T	F237L	0.994
5:181260105:A:G	F237L	0.994
5:181260265:G:C	C183W	0.994
5:181260696:A:G	C40R	0.994
5:181260700:G:C	N38K	0.994
5:181260700:G:T	N38K	0.994
5:181260755:C:G	C20S	0.994
5:181260755:C:T	C20Y	0.994
5:181260756:A:T	C20S	0.994
5:181260078:A:G	C246R	0.993
5:181260212:A:G	L201P	0.993
5:181260271:G:C	F181L	0.993
5:181260271:G:T	F181L	0.993
5:181260273:A:G	F181L	0.993
5:181260686:C:G	C43S	0.993
5:181260687:A:T	C43S	0.993

dbSNP variants (sampled 300 via entrez): RS1000112663 (5:181261439 T>C), RS1000258615 (5:181250261 C>G,T), RS1000279735 (5:181251216 C>G,T), RS1000312441 (5:181262176 T>C), RS1000538403 (5:181257476 T>A,C), RS1000597485 (5:181249643 T>TCCAGC), RS1000670105 (5:181262625 G>C), RS1000885399 (5:181256701 T>C), RS1001094762 (5:181250492 C>A,T), RS1001154097 (5:181255510 T>C,G), RS1001280791 (5:181252619 G>T), RS1001399746 (5:181261342 C>T), RS1001434909 (5:181255142 A>C), RS1001670841 (5:181248870 G>A), RS1001699435 (5:181249117 C>T)

Disease associations

OMIM: gene MIM:619265 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression	2
Cyclosporine	decreases expression	2
triphenyl phosphate	affects expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
trichostatin A	affects expression	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
beta-methylcholine	affects expression	1
K 7174	increases expression	1
Temozolomide	decreases expression	1
Leflunomide	decreases expression	1
Air Pollutants	decreases expression	1
Doxorubicin	decreases expression	1
Quercetin	decreases expression	1
Selenium	decreases expression	1
Dihydrotestosterone	increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TU34	HAP1 TRIM52 (-) 1	Cancer cell line	Male
CVCL_TU35	HAP1 TRIM52 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.